Back to search

Article

Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

2024-08-26

Abstract excerpt

Acyclovir is a primary treatment for central nervous system (CNS) infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV). However, patient outcomes remain suboptimal with high mortality and morbidity, following current dosing guidelines. Given the lack of alternative therapies, there is a pressing need to optimize acyclovir dosing, especially since initial regimens were developed in the 1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a0c0b18c-73fc-5411-8502-505a0365073e
DOI
10.1101/2024.08.25.24312421
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approachDOI 10.1101/2024.08.25.24312421
Nonlinear Mixed-Effects and Full Bayesian Population Pharmacokinetic Analysis of Ceftolozane–Tazobactam in Critically Ill PatientsSemantic proximity
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Semantic proximity
Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical SettingsSemantic proximity
Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected PatientsSemantic proximity
Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly PopulationSemantic proximity
Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Semantic proximity
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Semantic proximity
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Semantic proximity
Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization.Semantic proximity
Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.Semantic proximity
Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir DispositionSemantic proximity
Advancements in Virtual Bioequivalence: Computational Methods and Regulatory Perspectives in the Pharmaceutical IndustrySemantic proximity
Select a neighboring publication to make it the new centre.